New epidemiologic trends in cholangiocarcinoma.


Journal

Clinics and research in hepatology and gastroenterology
ISSN: 2210-741X
Titre abrégé: Clin Res Hepatol Gastroenterol
Pays: France
ID NLM: 101553659

Informations de publication

Date de publication:
11 2023
Historique:
received: 11 06 2023
revised: 14 09 2023
accepted: 02 10 2023
medline: 10 11 2023
pubmed: 6 10 2023
entrez: 5 10 2023
Statut: ppublish

Résumé

Cholangiocarcinoma (CCA) is the most common biliary tract malignancy and the second most frequent primary hepatic malignancy after hepatocellular carcinoma. During the past three decades, the incidence of intrahepatic cholangiocarcinoma (iCCA) has risen in Western Europe, while the incidence of extrahepatic cholangiocarcinoma (eCCA) has remained stable or fallen. The mortality rates of iCCA, which are greater than those of eCCA, showed also an increasing trend, while those of eCCA remained stable. Well-known risk factors like hepatobiliary flukes, hepatolithiasis and choledochal cysts are important in the development of iCCA particularly in Asian countries. In Western countries, the primary sclerosing cholangitis is the most common risk factor for CCA. Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection and cirrhosis are considered to be risk factors for iCCA. Emergent risk factors such as obesity, diabetes and MAFLD are increasingly associated mostly with iCCA.

Identifiants

pubmed: 37797807
pii: S2210-7401(23)00148-1
doi: 10.1016/j.clinre.2023.102223
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

102223

Informations de copyright

Copyright © 2023. Published by Elsevier Masson SAS.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare no conflict of interest regarding this article.

Auteurs

Alina Pascale (A)

Hepato-Biliary Department, Paul Brousse Hospital, APHP, 14 Avenue Paul Vaillant Couturier, 94800 Villejuif, France; INSERM U1193, Université Paris-Saclay, France; FHU Hepatinov, France. Electronic address: alina.pascale@aphp.fr.

Olivier Rosmorduc (O)

Hepato-Biliary Department, Paul Brousse Hospital, APHP, 14 Avenue Paul Vaillant Couturier, 94800 Villejuif, France; INSERM U1193, Université Paris-Saclay, France; FHU Hepatinov, France; Sorbonne Université, Paris, France.

Jean-Charles Duclos-Vallée (JC)

Hepato-Biliary Department, Paul Brousse Hospital, APHP, 14 Avenue Paul Vaillant Couturier, 94800 Villejuif, France; INSERM U1193, Université Paris-Saclay, France; FHU Hepatinov, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH